- Home
- SOGP vs PMCB Comparison
SOGP vs PMCB Comparison
Compare SOGP & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- PMCB
- Stock Information
- Founded
- SOGP 2010
- PMCB 1996
- Country
- SOGP Singapore
- PMCB United States
- Employees
- SOGP N/A
- PMCB N/A
- Industry
- SOGP
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOGP
- PMCB Health Care
- Exchange
- SOGP NYSE
- PMCB Nasdaq
- Market Cap
- SOGP 12.8M
- PMCB 13.9M
- IPO Year
- SOGP 2020
- PMCB N/A
- Fundamental
- Price
- SOGP $1.69
- PMCB $1.70
- Analyst Decision
- SOGP
- PMCB
- Analyst Count
- SOGP 0
- PMCB 0
- Target Price
- SOGP N/A
- PMCB N/A
- AVG Volume (30 Days)
- SOGP 11.8K
- PMCB 54.4K
- Earning Date
- SOGP 12-03-2024
- PMCB 12-13-2024
- Dividend Yield
- SOGP N/A
- PMCB N/A
- EPS Growth
- SOGP N/A
- PMCB N/A
- EPS
- SOGP N/A
- PMCB 0.54
- Revenue
- SOGP $298,906,204.00
- PMCB N/A
- Revenue This Year
- SOGP $37.39
- PMCB N/A
- Revenue Next Year
- SOGP $3.88
- PMCB N/A
- P/E Ratio
- SOGP N/A
- PMCB $3.18
- Revenue Growth
- SOGP N/A
- PMCB N/A
- 52 Week Low
- SOGP $1.49
- PMCB $1.39
- 52 Week High
- SOGP $6.70
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- SOGP 44.38
- PMCB 46.45
- Support Level
- SOGP $1.58
- PMCB $1.57
- Resistance Level
- SOGP $1.79
- PMCB $1.92
- Average True Range (ATR)
- SOGP 0.12
- PMCB 0.16
- MACD
- SOGP 0.00
- PMCB -0.01
- Stochastic Oscillator
- SOGP 34.07
- PMCB 36.84
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a global audio-centric social and entertainment company. It Leverages broad product portfolio and advanced in-house technologies, Sound Group caters to global user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions worldwide.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.